Obalon therapeutics inc (OBLN)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Revenue:
Revenue

3,300

9,101

9,914

-

-

-

Revenue

-

-

-

0

216

1,683

Revenue, related party

-

-

-

3,393

3,823

1,856

Revenues

-

-

9,900

3,393

4,039

3,539

Cost of revenue

2,950

5,423

4,829

2,809

2,503

2,912

Gross profit

331

3,678

5,085

584

1,536

627

Operating expenses:
Research and development

6,893

10,697

10,647

9,872

12,978

5,767

Selling, general and administrative

16,668

29,946

28,829

10,217

3,491

4,700

Total operating expenses

23,561

40,643

39,476

20,089

16,469

10,467

Loss from operations

-23,230

-36,965

-34,391

-19,505

-14,933

-9,840

Interest expense, net

-385

-226

-135

-477

-549

-220

Loss from change in fair value of warrant liability

-

-

-

466

34

-167

Other expense

-61

-189

-239

-19

-41

3

Net Income (Loss) Attributable to Parent

-23,676

-37,380

-34,765

-20,467

-15,557

-9,890

Other Comprehensive Income (Loss), Net of Tax

0

5

-4

-1

5

9

Net loss and comprehensive loss

-23,676

-37,375

-34,769

-20,468

-15,552

-9,881

Net loss per share, basic and diluted (in dollars per share)

-5.03

-19.64

-2.08

-4.85

-27.14

-18.61

Weighted-average common shares outstanding, basic and diluted (in shares)

4,706

1,903

16,717

4,221

573

531